Sahil Khera

Dad to Twin 👦•Husband• Interventional Director, Structural Heart Program, Mount Sinai Fuster Heart Hospital, NYC •Associate Professor• Tweets are my own views

[Pi-Cardia @Pi_Cardia]

💡 Advancing real-world experience with ShortCut in complex ViV-TAVR patients

The largest published commercial experience with ShortCut provides real-world evidence from 150 patients treated across 28 U.S. centers, including >50% first-time users.

Key findings include:
✅ >99% leaflet-splitting success, including 57% dual leaflets
✅ >36% of patients were treated for failed TAV
✅ >87% of patients were high risk for acute coronary compromise

Despite treating a highly challenging patient population, these results support the feasibility, reproducibility, and safety of ShortCut mechanical leaflet modification to help prevent coronary obstruction during complex ViV procedures.

💚A sincere thanks the investigators, authors, advisors, and participating centers for their collaboration and contributions to this important publication.

📖 Read more at: https://t.co/2bKqhYbrj3

@JACCJournals @RajMakkar @aakriti_15 @IgnacioInglessis-Azuaje @CurtissStinis, @PradeepYadavMD @VinodThourani @StanleyChetcuti @MatthewSummers @VivekPatel @BassemChehab @patelapurva @GilbertTangMD @KHERA_MD @MichaelRinaldi @tjsimard @JeffreySouthard @BenjaminStripe @whisenant_brian @KeithAllen @YosephRozenman @DvirDanny @CarlosSanchez, M.D. @PopmaJeffrey @MartyBLeon @PhilGenereuxMD

#JACC #NYValves2026 #NYValves #PiCardia #ShortCut #AorticValve #AorticStenosis #Cardiology #complexTAVR #Innovation #leafletlaceration #leafletmodification #leafletsplitting #LifetimeManagement #LifetimeManagementofAS #MedicalInnovation #medtech #Partnership #startuphealth #StructuralHeart #TAVI #TAVR #THV #transcatheter #valvefailure #VIV #ValveinValve #ViVTAVR #StructuralHeart

[Sahil Khera @KHERA_MD]

@jtsaxon Half cash / half stock!

[Sahil Khera @KHERA_MD]

@DoctorKini Leading the way in intravascular imaging! Congratulations AK , Amit and team!!

[Sahil Khera @KHERA_MD]

@MGtberg @GilbertTangMD @DoctorKini @DLBHATTMD @MountSinaiHeart 8F non expanded. Expanded approx 12F.

[Sahil Khera @KHERA_MD]

@SachinGoelMD @biljana_parapid @HMethodistMD Amazing, Sachin ! Looking forward to the data.

[Sahil Khera @KHERA_MD]

Exciting milestone at @MountSinaiHeart! We’re proud to have performed the FIRST #MIRUS #Siegel valve implantation at our center and New York as part of the #STARtrial. A new chapter in the #TAVR landscape begins. Stay tuned — the future of structural heart disease is here. 🫀 #StructuralHeart #Innovation

[Sahil Khera @KHERA_MD]

@azeemlatib @MontefioreNYC @AnterisTech @MonteHeart Congratulations!!! Azeem & team.

[SCAI @SCAI]

Live from La Raza, Mexico City—LAA rotablation case underway at #SCAI2026 🌎

One of many global live cases bringing real-world technique and decision-making directly to attendees.

#InterventionalCardiology #CardioX @KHERA_MD @drptca @ParasuramMD @kevin_tijerina

[Dr. Gilbert Tang @GilbertTangMD]

JUST OUT #JAMA the real-world US experience of Evoque #TTVR in >1000 pts from the TVT registry, showing encouraging 30d outcomes vs TRISCEND 2, among 82 trial and early commercial sites, with early commercial experience. Key takeaways:

- Mean age 77, 69% female, 73% NYHA III/IV, 91% prior HFH, 84% AF, 38% prior CIED, 68% on anticoagulation
- 40/40 split on primary vs secondary TR, 9% CIED related TR
- Interestingly, 40% mod/severe MR!
- 26 cases done via IJ
- 50/50 split between 44/48 vs 52/56 mm sizes
- 1 TTVR embolization/6 migration (in-hospital, none after), 8 acute surgical conversion, LOS 2 days post TTVR, 94% D/C home
- 30d: 3% all-cause, 2% CV mortality, 3.1% HFH, 15.9% pacemaker, 1.4% bleeding at access site / major vascular complication, 2.2% unplanned cardiac interventions, 1.3% cardiac arrest, 0.5% TV reintervention, 0.4% lead dislodgement/dysfunction, 0.6% cardiac perforation
- 98% mild or less TR, near TR elmination
- 94% on anticoagulation post TTVR
- Predictor of pacemaker: larger Evoque sizes; no predictors of bleeding

Pretty remarkable results in this sick population requiring complex TEE +/- ICE guidance. We are proud to be one of the early commercial sites to offer this therapy to our patients @MountSinaiHeart

Congrats to all investigators for their brave efforts in bringing this therapy to US patients! Future procedural and technology refinements should improve this therapy further!

FULL TEXT here:
https://t.co/ouiKF82w1R

@MountSinaiNYC
@IcahnMountSinai
@DoctorKini
@KHERA_MD
@LucySafi
@georgedangas
@DLBHATTMD
@Dr_BrendanCarr
@DrDavidReich
@BethOliverVP

[JACC Journals @JACCJournals]

Early U.S. experience with the Navitor valve demonstrates favorable early clinical and hemodynamic outcomes, with improved #PPI rate associated with procedural experience. https://t.co/vNXI01N2Wt

#JACCINT #TAVR #TVTRegistry @GilbertTangMD @KHERA_MD @PradeepYadavMD

[Dr. Gilbert Tang @GilbertTangMD]

Thank you #MateoMarinCuartas my co-Guest Editor, and all the co-authors from around the world, in the spirit of a multidisciplinary heart team of surgeons, interventional cardiologists, imagers, FITs (fellows in training), on the important topic of #TricuspidValve disease, published as a special edition in #AnnalsofCardiothoracicSurgery showcasing the importance of decision making of surgery vs transcatheter treatment #T-TEER #TTVR.

Full text on all the papers below:
https://t.co/exXZv9oOZ4

I'm particularly proud to present our own @MountSinaiHeart Step-by-Step Primer on Performing #Mitral and #Tricuspid #TEER, for the first time showing how the 2 procedures can relate each other, to facilitate procedural safety and efficiency, in a manner that is easy to understand.
https://t.co/UXdLdmhSic

Full lecture video here:
https://t.co/bSP3qY4IUf

On my YouTube channel
https://t.co/gmVokCkCDZ

@MountSinaiNYC
@IcahnMountSinai
@DoctorKini
@KHERA_MD
@LucySafi
@Dr_BrendanCarr
@DrDavidReich

[DoctorKini @DoctorKini]

I’m happy to share that our YELLOW-III study has been published in JACC: Cardiovascular Imaging. 110 stable coronary artery disease patients receiving maximally tolerated statin therapy were treated with evolocumab 140mg every 2 weeks for 26 weeks.
https://t.co/vMfkYyBhwQ

[Sachin Goel @SachinGoelMD]

Great connecting with IC friends #CRT2026 @PradeepYadavMD @kashishgoelmd @KHERA_MD @sameergafoor @SidakpalP

[Sahil Khera @KHERA_MD]

@PradeepYadavMD @PiedmontHealth @ACCinTouch @SCAI Congratulations!!

[Sahil Khera @KHERA_MD]

@jrouldz CRM

[Sahil Khera @KHERA_MD]

@amitisinvesting Not sure about international equities at this point unless it’s a large value. Better opportunities in the US market. But all the best my friend. You are doing a great job and love reading your tweets.

[Sahil Khera @KHERA_MD]

@StevenYakubov @igeorge1975 @OKhaliqueMD @TheLADoctor @npfam1 @anvoramd @AkhilNarangMD @bapat_savrtavr

[Sahil Khera @KHERA_MD]

Thank you @CathElectroSurg for sharing ! Top faculty like yourself made @NytvL an engaging educational program. Looking forward to the next one Feb 5th 2027 - mark your calendar. @MountSinaiHeart @SCAI @scaielm @DLBHATTMD @MountSinaiNYC @GilbertTangMD @ccclivecases @DoctorKini

[Jaffar Khan @CathElectroSurg]

9 live cases today at NYTVS - great program ⁦@GilbertTangMD⁩ ⁦@KHERA_MD⁩ ⁦@LucySafi⁩ ⁦@OKhaliqueMD⁩

[New York Transcatheter Valves Symposium @NytvL]

Catch the end of the debate LIVE: https://t.co/Iv1y0CXGht

DEBATE: TAVR is Preferred Over SAVR in the Lifetime Management of Young, Low-risk Patients

YES, We Can Do Redo-TAVR!:  Eberhard Grube, MD
NO, We Can Put a BIG Surgical Valve for TAV-in-SAV:  Vinayak N. Bapat, MD

[New York Transcatheter Valves Symposium @NytvL]

NYTVS IS THIS WEEK! Don't miss out on 9 live cases, key insights from outstanding faculty, and networking with renowned leaders in the field 🫀

📆December 11, 2025
📍 The Mount Sinai Hospital

Register NOW: https://t.co/qJsW6hwXAy

#Cardiology #Cardiotwitter #StructuralHeart